Boston Biomedical, Inc. is a leading developer of next-generation cancer therapeutics designed to inhibit multiple oncogenic pathways, including cancer stemness pathways, and modify immune responses. Tolero Pharmaceuticals, Inc. is a leading developer of novel therapeutics to inhibit biologic drivers of hematologic and oncologic diseases. Both companies are based in the United States and are wholly owned by Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan. Please visit www.BostonBiomedical.com and www.ToleroPharma.com.